0000000000174088

AUTHOR

Reina Armamento-villareal

showing 6 related works from this author

Increased 2-Hydroxylation of Estrogen in Women with a Family History of Osteoporosis

2005

Recent studies indicate that women with predominant estrogen metabolism through the 2-hydroxyl (inactive) pathway have lower bone mineral density (BMD) compared with those with predominant 16alpha-hydroxylation (active). Although many factors have been identified to affect estrogen metabolism, the role of a family history of osteoporosis remains unknown. The objective of this study was to investigate the influence of family history of osteoporosis and other clinical factors on estrogen hydroxylation. This was a cross-sectional study conducted in a university-based research center from May 2002 to February 2004. The participants included 175 otherwise healthy postmenopausal women at least 1 …

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismUrinary systemClinical BiochemistryOsteoporosisHydroxylationBiochemistryArticleHydroxylationchemistry.chemical_compoundEndocrinologyBone DensityInternal medicinemedicineHumansosteoporosiFemurFamily historyAgedBone mineralPostmenopausal womenbusiness.industryBiochemistry (medical)EstrogensMiddle Agedmedicine.diseaseEstrogenCross-Sectional StudiesEndocrinologychemistryEstrogenOsteoporosiswomen health.CalciumFemalebusinessThe Journal of Clinical Endocrinology & Metabolism
researchProduct

The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density.

2009

Polymorphisms of the CYP450 genes that encode for the enzymes that metabolize estrogen are linked to hormone-related cancers. We investigated the impact of two polymorphisms of the CYP1B1 gene previously reported to be associated with hormone-related disorders on estrogen metabolism and bone mineral density (BMD), another hormone-dependent condition, in women from different ethnic backgrounds. Four hundred sixty-eight postmenopausal Caucasian women, 220 from St. Louis, MO, USA (mean age=63.5+/-0.53 years) and 248 from Palermo, Italy (mean age=72.9+/-0.44 years) participated in the study. Measurements of urinary estrogen metabolites by enzyme-linked immunoassay, serum estradiol by ultrasensi…

medicine.medical_specialtyHistologyBone densityGenotypePhysiologymedicine.drug_classEndocrinology Diabetes and MetabolismOsteoporosisHypoestrogenismBiologyArticleBone DensityLeucineRisk FactorsInternal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseAlleleFemoral neckPolymorphism GeneticEstrogensValineMiddle Agedmedicine.diseaseMenopausemedicine.anatomical_structureEndocrinologyEstrogenCytochrome P-450 CYP1B1FemaleAryl Hydrocarbon HydroxylasesBone
researchProduct

Effects of polymorphisms of the sex hormone-binding globulin (SHBG) gene on free estradiol and bone mineral density.

2009

Polymorphisms of the sex hormone-binding globulin (SHBG) gene are associated with differences in SHBG levels, influencing the risk for breast cancer and polycystic ovarian syndrome, but no association has been reported for osteoporosis in postmenopausal women.To determine the effect of G to A substitution in the 5'UTR (rs1799941) and the Asp356Asn (rs6259) polymorphisms of the SHBG gene on bone mineral density (BMD).This is a cross-sectional study in a university-based research center from May, 2002 to December, 2007. A total of two hundred and thirteen healthy postmenopausal Caucasian womenor = 1 year from last menstrual period participated to this study. Serum estradiol by ultrasensitive …

medicine.medical_specialtyHistologyBone densityGlobulinGenotypePhysiologyEndocrinology Diabetes and MetabolismOsteoporosisBiologyPolymorphism Single NucleotideArticleBreast cancerSex hormone-binding globulinBone DensityInternal medicineSex Hormone-Binding GlobulinGenotypemedicineHumansBone mineralImmunoradiometric assayEstradiolMiddle Agedmedicine.diseaseEndocrinologybiology.proteinFemale5' Untranslated RegionsBone
researchProduct

Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects

2020

Objective: In obese men, the increased expression of the aromatase enzyme in adipose tissue leads to high conversion of androgens to estrogens contributing to hypogonadotropic hypogonadism (HHG). Our objective is to evaluate efficacy and safety of weight loss (WL) plus aromatase inhibitor (AI) therapy in severely obese men with HHG. We hypothesize that AI+WL will be more effective as compared to WL alone in improving the hormonal profile, thus muscle strength and symptoms of HHG (primary outcomes), with no significant adverse effects on lean mass, metabolic profile, and bone mineral density (secondary outcomes).Design: Randomized double-blind placebo-controlled pilot trial.Methods: Twenty-t…

Male0301 basic medicineobesityBone densityEndocrinology Diabetes and MetabolismPilot Projectslcsh:Diseases of the endocrine glands. Clinical endocrinologyaromatase inhibitorsEndocrinology0302 clinical medicineBone DensityWeight lossMedicineTestosteroneTestosteroneBone mineralEstradiolMiddle AgedPrognosisClinical TrialAndrogensMetabolomemedicine.symptombone microarchitecturemedicine.drugAdultmedicine.medical_specialtyHormone Replacement Therapymedicine.drug_classAnastrozole030209 endocrinology & metabolismsex hormonesBone and Bones03 medical and health sciencesDouble-Blind MethodHypogonadotropic hypogonadismInternal medicineWeight LossHumanshypogonadismMuscle StrengthAgedbody compositionlcsh:RC648-665Aromatase inhibitorbusiness.industrymedicine.disease030104 developmental biologyEndocrinologyLean body massbusinessBiomarkersFollow-Up StudiesFrontiers in Endocrinology
researchProduct

Estrogen metabolism modulates bone density in men.

2007

Estrogen is a critical hormone for bone homeostasis in men, but no information is available on the role of estrogen metabolism among men. The aim of this study was to evaluate the effect of estrogen hydroxylation on male bone mineral density (BMD). Participants consisted of 61 healthy Caucasian males (mean age 66.6 +/- 1.0 years). Urinary estrogen metabolites were measured by enzyme-linked immunosorbent assay, serum estradiol by ultrasensitive radioimmunoassay, sex hormone binding globulin by radioimmunoassay, and BMD of the lumbar spine and the proximal femur by dual-energy X-ray absorptiometry. Active estrogen metabolites, 16alpha-hydroxyestrone (16alphaOHE(1)) and estriol (E(3)), positiv…

musculoskeletal diseasesMalemedicine.medical_specialtyBone densitymedicine.drug_classEndocrinology Diabetes and MetabolismMotor ActivityHydroxylationArticleBody Mass IndexEndocrinologySex hormone-binding globulinBone DensityInternal medicinemedicineHumansOrthopedics and Sports MedicineFemoral neckAgedBone mineralAged 80 and overbiologyChemistryEstriolEstriolRadioimmunoassayEstrogensMiddle Agedmusculoskeletal systemEndocrinologymedicine.anatomical_structureCross-Sectional StudiesSteroid 16-alpha-HydroxylaseEstrogenbiology.proteinBody mass indexCalcified tissue international
researchProduct

Effect of CYP1A1 Gene Polymorphisms on Estrogen Metabolism and Bone Density

2004

UNLABELLED: In this study, we evaluated the effect of polymorphisms of the CYP1A1 gene, linked to hormone-related cancers, on estrogen metabolism and BMD. We found that variants carrying the A allele (CA and AA) for the C4887A polymorphism have a significantly higher degree of estrogen catabolism and lower femoral BMD. INTRODUCTION: Polymorphisms of the CYP1A1 gene, one of the key enzymes that metabolize estrogen, have been linked with hormone-related cancers. We investigated the impact of these polymorphisms on estrogen metabolism and BMD, which is another hormone-dependent health issue. MATERIALS AND METHODS: One hundred seventy postmenopausal women (mean age, 63.5 +/- 0.6 years) particip…

medicine.medical_specialtyTime FactorsGenotypeBone densitymedicine.drug_classEndocrinology Diabetes and MetabolismOsteoporosisRadioimmunoassayBiologyArticleCollagen Type IBone resorptionImmunoenzyme TechniquesAbsorptiometry PhotonBone DensityRisk FactorsInternal medicinehormones and receptorGenotypeCytochrome P-450 CYP1A1medicineHumansosteoporosiOrthopedics and Sports MedicineFemurBone ResorptionAllelesAgedPolymorphism GeneticEstradiolgenetic researchEstrogensMiddle Agedmedicine.diseaseGenotype frequencyPostmenopauseMenopauseEndocrinologyEstrogenepidemiologyFemaleCollagenGene polymorphismMenopausePeptidesPolymorphism Restriction Fragment LengthJournal of Bone and Mineral Research
researchProduct